Bio­Car­dia paus­es en­roll­ment in PhI­II tri­al of heart fail­ure stem cell ther­a­py

Bio­Car­dia has paused en­roll­ment in a piv­otal study of its stem cell ther­a­py for heart fail­ure af­ter an in­de­pen­dent re­view board de­ter­mined the tri­al was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.